Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 2Phase 1 2

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 13Breast 5Sarcoma 4Gastrointestinal 4Thoracic 2Dermatologic 2Tumor-Agnostic 1Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Melanoma 2

Interventions

pembrolizumab 81Nivolumab 55Ipilimumab 44Cyclophosphamide 38aldesleukin 26Interleukin-2 25fludarabine 17Temozolomide 17fludarabine phosphate 16trametinib 11dabrafenib 11Radiotherapy 11Biopsy 11avelumab 10Paclitaxel 9spartalizumab 8cemiplimab 8Dacarbazine 8Cisplatin 8Bevacizumab 8sargramostim 7binimetinib 7Fluorouracil 7poly ICLC 6lenvatinib 6epacadostat 6atezolizumab 6Magnetic Resonance Spectroscopy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Sunitinib × Dermatologic × Clear all
NCT00496223 2011-02-23

A Phase I/II Study of Sunitinib and Dacarbazine

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Terminated
11 enrolled
Dermatologic

Melanoma

NCT00304200 2009-02-05

Temodar and Sutent as Therapy for Melanoma

Northern California Melanoma Center

Phase 1/2 Terminated
7 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡